ABPRO HOLDINGS INC (ABP) Stock Price, Forecast & Analysis
NASDAQ:ABP • US0008472021
ABP Key Statistics, Chart & Performance
The current stock price of ABP is 0.6323 USD. In the past month the price decreased by -79.35%. In the past year, price decreased by -97.64%.
ABP Technical Analysis
ABP Financial Highlights
Over the last trailing twelve months ABP reported a non-GAAP Earnings per Share(EPS) of -24.36. The EPS decreased by -361.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1294.36% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABP Forecast & Estimates
ABP Ownership
ABP Latest News, Press Relases and Analysis
ABP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 409.148B | ||
| AMGN | AMGEN INC | 16.61 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.32 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.94 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.67 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.82 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.11 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABP
Company Profile
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Company Info
ABPRO HOLDINGS INC
6 St Johns Lane, Floor 5
New York City NEW YORK US
Employees: 11
Phone: 12488907200
ABPRO HOLDINGS INC / ABP FAQ
What does ABP do?
Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
What is the stock price of ABPRO HOLDINGS INC today?
The current stock price of ABP is 0.6323 USD. The price decreased by -14.55% in the last trading session.
Does ABPRO HOLDINGS INC pay dividends?
ABP does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABP stock?
ABP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ABP stock?
ABPRO HOLDINGS INC (ABP) operates in the Health Care sector and the Biotechnology industry.